Microglia-Neuron Interaction
Neuroscience
1 Career
- Since 2025 Life Sciences Research Area Chair, Institute of Science and Technology Austria (ISTA)
- Since 2023 Professor, Institute of Science and Technology Austria (ISTA)
- Since 2023 Co-Founder and Consultant of the spin-off Syntropic Medical GmbH
- 2015 – 2023 Assistant Professor, Institute of Science and Technology Austria (ISTA)
- 2011 – 2014 Postdoc, MIT, The Picower Institute for Learning and Memory, Cambridge, MA, USA
- 2010 – 2011 Postdoc, FMI, Basel, Switzerland
- 2010 PhD, University of Basel, Basel, Switzerland, work performed at the FMI
1.1 Selected Distinctions
- 2025 Recognition Prize, Lower Austrian Science Awards
- 2024 Co-Organizer of ISTA-FKNE-CHET Young PI Symposium at FENS
- 2023 Founder of ATglia.net, an Austrian network of research groups interested in questions related to glia cells.
- 2019 Neuroscience 2019 “Hot Topic”, Society of Neuroscience, Chicago, USA
- 2017 Liese Prokop-Frauenpreis for science and technology, Lower Austria, Austria
1.2 Selected Grants
- 2026 EIT-HEALTH-DTVB – shAIpe(2024-DTVBP-11012), Segmentation of High-dimensional data using AI for Precise Evaluation. Awarded to RG: € 59,999.
- 2024 – 2025 HE-ERC-PoC- SYNTROPIC (101138423), 60-Hz light entrainment to unlock mental health conditions. Awarded to RG: € 150,000.
- 2023 – 2026 FWF-StA- P37131, Dissecting the morpho-functional relationship of microglia. Awarded to RG: € 447,764.05.
1.3 Tech Transfer (Patents, Spin-Offs)
- 2023 Founding of spin-off Syntropic Medical GmbH
- 2019 Induction of Neuroplasticity using ketamine and pulsed light. 18/10/2019. Patent application: CA3156658, IL292155, US2023/0095907, CN114555166, EP4045139, EP 4497471. Venturino A, Siegert S.
- 2025 Biomedical Image Processing. 23/07/2025. Patent application: EPC 25191393.5. Alamalhoda MA, Siegert S, Venturino A, Firoozi A.
- 2026 Light treatment for PTSD. Patent application draft finalized; submission planned in spring. Muhia M, Siegert S, Venturino A.
- 2026 Macrophage phenotyping-on-a-chip for translational diagnostics and drug discovery. Ongoing evaluation. Korkut-Demirbaş M, Siegert S.
1.4 Selected Publications
- Venturino A, Schulz R, de Jesus-Cortex H, Reilly-Andujar F, Maes ME, Nagy B, Cubero RJA, Colombo G, Schoot Uiterkamp FE, Bear M, Siegert S, “Microglia dismantle mature perineuronal nets upon anesthetic ketamine exposure or 60-Hz light entrainment in the healthy brain”, Cell Reports, 2021, 36(1):109313, https://doi.org/10.1016/j.celrep.2021.109313.
- Colombo G, Cubero RJA, Kanari L, Venturino A, Schulz R, Scolamiero M, Agerberg J, Mathys H, Tsai L-H, Chachólsk W, Hess K, Siegert S, “A tool for mapping microglial morphology, morphOMICs, reveals brain-region and sex-dependent phenotypes”, Nature Neuroscience, 2022, 25(10):1379-1393. https://doi.org/10.1038/s41593-022-01167-6.
- Schulz R, Korkut-Demirbaş M, Colombo G, Siegert S, “Chimeric GPCRs mimic distinct signaling pathways and modulate microglia responses”, Nature Communication, 2022, 13(1):4728, https://doi.org/10.1038/s41467-022-32390-1.
- Schmied V, Korkut-Demirbaş M, Venturino A, Siegert S, “Microglia determine an immune-challenged environment and facilitate ibuprofen action in human retinal organoids”, J. of Neuroinflammation, 2025 Apr 3; 22(1):98. https://10.1186/s12974-025-03366-x.
- Maes ME, Colombo G, Schoot Uiterkamp FE, Sternberg F, Venturino A, Pohl EE, Siegert S, “Mitochondrial network adaptations of microglia reveal sex-specific stress response after injury and UCP2 knockout”, iScience, 2023 Aug 29;26(10):107780. https://doi.org/10.1016/j.isci.2023.107780.
2 Group Members
- Medina Korkut-Demirbaş, PhD Student since 2022
- Natalie Yildiz Özgen, PhD Student since 2019
- Athina Boutou, Postdoc since 2026
- Alessandro Venturino, Research Technician since 2016
3 Research
Brain dysfunction significantly impacts daily life, yet its underlying causes remain poorly understood. Rather than focusing on disease models that capture only limited symptoms, we investigate how the mature brain forms lasting memories from new environmental inputs while preserving existing ones. Environmental factors such as stress, drugs, hormones, and nutrition affect neuronal function and, if not optimally balanced, can lead to disease.
We propose that microglia play a central role in this process. Traditionally viewed as immune cells that detect and clear pathogens, microglia respond rather inefficiently during infections, causing further tissue damage. Recent in vivo imaging emphasizes that they actively interact with neurons rather than act as passive bystanders. Microglia sense and respond to both cues and neuronal signals. If microglia misinterpret or miscommunicate, this will disrupt neuronal network function. Like poor communication in daily life, leading to conflicts.
To address microglia-neuron communication, we focus on the mouse brain and model human-related aspects with induced pluripotent stem cells (hIPSCs). By connecting our knowledge from virology, immunology, molecular and cellular biology, behavioral neuroscience, and epigenetics with concepts from applied mathematics and machine learning, we are uniquely positioned to discover the impact of microglia in the nervous system.
3.1 Current Scientific Projects/Directions
- Disentangle the morph-functional relationship of microglia
- Microglia migration through the extracellular space in mouse and humans
- Environmental cue-driven microglia-induced changes in the neuronal network
3.2 Research in Focus
The brain’s flexibility to learn is partially restricted by defined extracellular matrix structures, such as perineuronal nets (PNN), which lock neurons into a functional state. In our line of research, we uncovered that we can “reopen” the adult brain’s locked neurons through ketamine, a substance already explored in mental health treatment. Ketamine enables microglia to remodel the PNN and temporarily restores juvenile-like plasticity. In follow-up studies, we found that (i) ketamine has a similar effect on microglia in human temporal lobe tissue, and (ii) females respond to this ketamine faster than males through a microglia-mediated mechanism to regulate the stress-associated hormone corticosterone. This provides important new insights for developing more personalized and effective treatments.
Building on the initial discovery, we developed a non-invasive strategy that mimics the ketamine-induced 60-Hz frequency using controlled light stimulation at the same frequency. Exposing the brain to this 60-Hz pulsed light produced similar beneficial effects on PNN without requiring ketamine. This simple and safe approach made it appealing to translate our basic research findings into real-world applications in mental health. Through the spin-off company Syntropic Medical GmbH, the technology is being further developed into a medical device and has reached clinical phase II. Preliminary results in patients with major depressive disorder demonstrated strong safety and significant positive therapeutic outcomes, with no to minimal reported side effects.
The results have been published in Venturino et al. Cell Reports, 2021; Venturino & Siegert, STAR Protocols 2021, with a Faculty Opinion Recommendation by Wu L & Bosco D. Follow-up studies in revision, and available on bioRxiv under Venturino et al. 2025, 2026. The related IP https://patents.google.com/patent/WO2021074448A1/de and spin-off company Syntropic Medical GmbH.